Péter Vörös

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs et al. · European Heart Journal · 2021 · 122 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Incidence, Paris Classification, and Follow‐up in a Nationwide Incident Cohort of Pediatric Patients With Inflammatory Bowel Disease

Katalin Eszter Müller, Péter L. Lakatos, András Arató et al. · Journal of Pediatric Gastroenterology and Nutrition · 2013 · 120 citations · Full text

Medicine, Child Health, Pediatrics +7

Neutral pH and low–glucose degradation product dialysis fluids induce major early alterations of the peritoneal membrane in children on peritoneal dialysis

Betti Schaefer, Maria Bartosova, Stephan Macher‐Goeppinger et al. · Kidney International · 2018 · 107 citations · Full text

Medicine, Pediatrics, Physiology +14

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

Hiddo J.L. Heerspink, David Z.I. Cherney, Douwe Postmus et al. · Kidney International · 2021 · 94 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Cardiac autonomic neuropathy and QT interval length. A follow-up study in diabetic patients.

György Jermendy, L Tóth, Péter Vörös et al. · PubMed · 1991 · 55 citations

Medicine, Endocrinology, Internal Medicine +7